Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
Status:
Completed
Trial end date:
2021-07-06
Target enrollment:
Participant gender:
Summary
This is an ongoing Phase 2, open-label, multicenter, non-randomized study of MEDI4736
(durvalumab) in subjects with glioblastoma (GBM) enrolled into 5 non-comparative cohorts.
Primary study objectives, which vary by cohort due to differences in subject populations,
include evaluation of the clinical efficacy as measured by the overall survival (OS) rate at
12 months (Cohort A), progression-free survival (PFS) at 6 months (Cohorts B, B2, and B3),
and OS at 6 months (Cohort C). For all cohorts, secondary objectives include evaluation of
the safety/tolerability and clinical efficacy of study treatment, and exploratory objectives
include evaluation of the neurologic function and correlative biomarkers.
Phase:
Phase 2
Details
Lead Sponsor:
Ludwig Institute for Cancer Research
Collaborators:
Cancer Research Institute, New York City Cure Brain Cancer Foundation, Australia MedImmune LLC